292 results
Page 4 of 15
8-K
EX-99.1
ftj3x78u
5 Dec 22
Diffusion has a highly engaged and independent board that possesses the right skills and experience to execute the strategic review process
9:58pm
DEFC14A
i84 feda01ko
5 Dec 22
Proxy in contested solicitation
5:12pm
PRER14A
jdxm5z510auikc1j
28 Nov 22
Preliminary revised proxy
5:17pm
PREC14A
23s0rxlvhtr0waadp
18 Nov 22
Preliminary proxy with contested solicitation
5:08pm
8-K
EX-99.1
u7n2x2 fni
18 Nov 22
Diffusion Pharmaceuticals Sees Significant Progress in its Strategic Review Process
4:40pm
DEFA14A
EX-99.1
e738jzqkok8if 31azir
14 Nov 22
Additional proxy soliciting materials
7:41am
8-K
EX-99.1
lka40wkqrof66cgvc
14 Nov 22
Diffusion Pharmaceuticals Sees Significant Progress in its Strategic Review Process
7:40am
8-K
EX-99.1
js537tqs
27 Oct 22
Diffusion Pharmaceuticals Announces Strategic Review Process to Evaluate Value-Enhancing Alternatives including Opportunities to Better Leverage TSC
4:15pm
8-K
EX-99.1
5bl 5ktaj81z3y7ezd
16 Aug 22
Diffusion Pharmaceuticals Reports Second Quarter 2022 Financial Results and Provides Business Update
4:21pm
8-K
EX-99.1
wz9ylq2f
27 Jul 22
Other Events
7:30am
8-K
EX-1.1
i3kzhvr4o94
22 Jul 22
Entry into a Material Definitive Agreement
4:20pm
424B5
gxx 4u1bm33zv27s5
22 Jul 22
Prospectus supplement for primary offering
4:15pm
8-K
EX-10.1
90184 0va
28 Jun 22
Diffusion Pharmaceuticals Announces Positive Effects in Altitude Trial
4:13pm
8-K
EX-99.1
2kjd48gq7wiy
28 Jun 22
Diffusion Pharmaceuticals Announces Positive Effects in Altitude Trial
4:13pm
8-K
EX-99.1
zm48un5
23 May 22
Diffusion Pharmaceuticals Announces Appointment of Raven Jaeger, M.S., as Chief Regulatory Officer
5:42pm
8-K
EX-99.1
msx6pvihhjqqr
16 May 22
Diffusion Pharmaceuticals Reports First Quarter 2022 Financial Results and Provides Business Update
12:00am